Tempest Therapeutics Inc
NASDAQ:TPST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tempest Therapeutics Inc
Cash from Investing Activities
Tempest Therapeutics Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
Cash from Investing Activities
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$6.6B
|
CAGR 3-Years
-120%
|
CAGR 5-Years
29%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$4.8B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
20%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$1.9B
|
CAGR 3-Years
31%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$945.4m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$629.1m
|
CAGR 3-Years
45%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
4%
|
|
Tempest Therapeutics Inc
Glance View
Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.
See Also
What is Tempest Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
0
USD
Based on the financial report for Dec 31, 2025, Tempest Therapeutics Inc's Cash from Investing Activities amounts to 0 USD.
